Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Vertex, fresh off an R&D miss, flashes data suggesting their sickle cell CRISPR therapy is working

5 years ago

JW Therapeutics hauls in $300M IPO just as liso-cel-inspired CAR-T nears the finish line in China

5 years ago

Promising mRNA tech comes with regulatory, CMC headaches

5 years ago

Eyeing commercialization, a Shanghai-based CAR-T startup nabs a $186M megaround

5 years ago

Sana Biotechnology snags Oscine, adding cell therapy leader Steve Goldman to its star-studded staff

5 years ago

Bellicum slashes 79% of staffers after early data quash hope around next-gen CAR-T

5 years ago

Novartis buys a new gene therapy for vision loss, and this is one preclinical venture that didn't come cheap

5 years ago

Bayer buys a biotech ‘race horse’ with a $4B deal — $2B in cash — aimed at going big into gene therapy

5 years ago

Ultragenyx injects $40M to grab Solid's microdystrophin transgene — while sidestepping the AAV9 vector that stirred up safety fears

5 years ago

Can B cells break the boundaries of cell therapy? Longwood startup has $52M to prove a new engineering tech

5 years ago

Bo Cumbo jumps from the top commercial post at Sarepta to the helm of a gene therapy startup with some influential backers, big plans and $107M

5 years ago

CRISPR Therapeutics gets a snapshot of off-the-shelf CAR-T success in B-cell malignancies — marred by the death of a patient

5 years ago

SparingVision raises $52M to kick off long journey for a next-gen gene therapy that goes much, much broader than Luxturna

5 years ago

CAR-plus: Irish biotech recruits Kite alum Chris Nowers to prep dual-targeting NK cell therapy for the clinic

5 years ago

FDA officials, experts discuss impact of Covid-19 on cell and gene therapies

5 years ago

Patient death in pivotal gene therapy trial rattles Sarepta partner already facing clinical hold

5 years ago

Roche turns to a Harvard upstart out of George Church’s lab to construct AAV 2.0 model vectors — a key part of building the gene therapy pipeline

5 years ago

Out to pioneer gene editing in China, EdiGene bags $67M to begin clinical testing for β-thalassemia therapy, universal CAR-T

5 years ago

Voyager shares take a hit as FDA slaps a hold on the IND for Huntington's gene therapy — their #2 play in the pipeline

5 years ago

A2 Biotherapeutics nabs $71M-plus Series B for selective cell therapy pipeline

5 years ago

Iovance shares hammered on TIL therapy filing delay — although analysts aren't as bothered

5 years ago

FDA gives thumbs down for Mesoblast's aGVHD drug, saying one single-arm trial is not enough

5 years ago

Mesoblast asks for trading halt as PDUFA date slides by. What's up?

5 years ago

Solid gets another shot in DMD gene therapy race as FDA lifts hold. But is it too late to catch Pfizer, Sarepta?

5 years ago

First page Previous page 43 44 454647 48 49 Next page Last page